Keywords: strong, 3rd-qtr, takeda, actos, candesartan, expand, globally
Strong 3rd-qtr for Takeda, as Actos and candesartan expand globally
Article | 21 February 2005
Leading Japanese drugmaker Takeda has reported strong consolidated results for the first three quarters (April-December 2004) of the fiscal year to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
